– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026
Globe Newswire
Original source
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026
Globe Newswire
Original source

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today’s Presidential Symposium II at the European Society for Medic

Here's how the seven parties plan to tackle the parenting deficit this election.

The findings highlight the importance of appropriate health management for government workers as concerns grow over long working hours.

Experts say it is essential to establish a support system to protect this vulnerable group from businesses that try to take advantage of them.
Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.
Read Disclaimer